MREONasdaqPharmaceutical PreparationsFiscal year ends December 31

Mereo BioPharma Group plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$0.30−0.00 (-0.30%)

Close on Oct 19, 2026

Market cap: $242.76M
P/E (TTM): –
Dividend yield: –

Mereo BioPharma Group plc cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Stock-Based Compensation	7.60	7.39	4.92	4.77
Deferred Income Taxes	–	0	0	0
Other Non-Cash Items	0	-1.75	0	2.00
Change in Accounts Payable	-1.38	0.15	-1.26	0.62
Operating Cash Flow	-31	-33	-21	-49
Capital Expenditures	-0.02	0	0	-0.01
Investing Cash Flow	-0.02	-0.70	-0.42	1.99
Stock Issued	0.04	47	12	0
Financing Cash Flow	0.33	46	7.97	0.20
Foreign Exchange Rate Adjustments	1.85	-0.23	2.82	-13
Net Change in Cash	–	12	-11	–
Free Cash Flow	-31	-33	-21	-49
Income Taxes Paid	–	0	-1.34	1.88
Interest Paid	0.03	0.02	0.88	0.02

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -6840.2%
Net margin: -5619.8%
Return on equity, FY2025: -82.2%

Financial strength

Current ratio: 5.88
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 530.5%

Valuation

P/E ratio: –
Price to sales: 485.51
Price to book: 8.47
Dividend yield: –